Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Tuspetinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose updates Tuspetinib-based triple drug therapy in AML trial
    Aptose updates Tuspetinib-based triple drug therapy in AML trial

    05 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/05/3073937/35575/en/Aptose-Provides-Clinical-Update-for-the-Tuspetinib-based-Triple-Drug-Frontline-Therapy-in-Newly-Diagnosed-AML-Patients-from-the-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    05 May 2025
    Share Share
    Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
    Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053375/35575/en/Aptose-Common-Shares-to-Delist-from-Nasdaq-as-of-April-2-2025.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Aptose Reports Year End 2024 Results and Corporate Highlights
    Aptose Reports Year End 2024 Results and Corporate Highlights

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051334/35575/en/Aptose-Reports-Year-End-2024-Results-and-Corporate-Highlights.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    Aptose Gets CSRC Nod To Escalate Dosing In Ph 1/2 Tuscany Trial
    Aptose Gets CSRC Nod To Escalate Dosing In Ph 1/2 Tuscany Trial

    20 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/20/3029546/35575/en/Aptose-Announces-Positive-Clinical-Safety-Review-Committee-CSRC-Approval-to-Dose-Escalate-in-Phase-1-2-Tuscany-Trial-of-Frontline-Triple-Drug-Therapy-with-Tuspetinib-Amid-Complete-.html

    GLOBENEWSWIRE
    20 Feb 2025
    Share Share
    Aptoses’ Tuspetinib Shows Responses In AML Ph 1/2 TUSCANY Trial
    Aptoses’ Tuspetinib Shows Responses In AML Ph 1/2 TUSCANY Trial

    12 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/12/3024897/35575/en/Aptose-s-Frontline-Triple-Drug-Therapy-with-Tuspetinib-Achieves-Notable-Responses-in-Newly-Diagnosed-AML-Patients-in-the-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    12 Feb 2025
    Share Share
    Aptose Begins Dosing AML Patients With Tuspetinib Triplet In Trial
    Aptose Begins Dosing AML Patients With Tuspetinib Triplet In Trial

    09 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/09/3007341/35575/en/Aptose-Announces-First-AML-Patients-Dosed-with-Tuspetinib-Triplet-Frontline-Therapy-in-TUSCANY-Trial.html

    GLOBENEWSWIRE
    09 Jan 2025
    Share Share